{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:36:14Z","timestamp":1782207374212,"version":"3.54.5"},"reference-count":31,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,4,26]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Vanishing bile duct syndrome is an uncommon condition characterised by the progressive loss and disappearance of bile ducts. It is an acquired form of cholestatic liver disease presenting with hepatic ductopenia (loss of &gt;50%\u2009bile ducts in the portal areas). We present a case of vanishing bile duct syndrome as a presentation of Hodgkin\u2019s lymphoma who was treated with standard-of-care chemotherapy\u2014doxorubicin, bleomycin, vinblastine and dacarbazine (along with brief administration of rituximab), which led to complete response and normalisation of liver function.<\/jats:p>","DOI":"10.1136\/bcr-2023-256818","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T22:45:12Z","timestamp":1716331512000},"page":"e256818","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Vanishing bile duct syndrome as a presentation of Hodgkin\u2019s lymphoma"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-6859","authenticated-orcid":false,"given":"Ifrah","family":"Fatima","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himil","family":"Mahadevia","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheshadri","family":"Madhusudhana","sequence":"additional","affiliation":[{"name":"Medicine, Section of Hematology and Oncology, University of Missouri Kansas City School of Medicine, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Medicine, Section of Hematology and Oncology, University of Missouri Kansas City School of Medicine, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2025082708312648000_17.5.e256818.1","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-7-529","article-title":"Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin\u2019s lymphoma: a case report and review of the literature","volume":"7","author":"Rota Scalabrini","year":"2014","journal-title":"BMC Res Notes"},{"key":"2025082708312648000_17.5.e256818.2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i2.366"},{"key":"2025082708312648000_17.5.e256818.3","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3748\/wjg.14.4111","article-title":"Liver in systemic disease","volume":"14","author":"Shimizu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2025082708312648000_17.5.e256818.4","doi-asserted-by":"crossref","unstructured":"Shionoya K , Kobayashi M , Kako M , et al . A case of drug-induced liver injury considered steroid-resistant and histologically diagnosed with vanishing bile duct syndrome. Intern Med 2024;2427\u201323. doi:10.2169\/internalmedicine.2427-23","DOI":"10.2169\/internalmedicine.2427-23"},{"key":"2025082708312648000_17.5.e256818.5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3109\/0284186X.2014.897001","article-title":"Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma \u2013 pathological development and restitution","volume":"53","author":"Hall\u00e9n","year":"2014","journal-title":"Acta Oncologica"},{"key":"2025082708312648000_17.5.e256818.6","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Beretta-Piccoli","year":"2017","journal-title":"WJG"},{"key":"2025082708312648000_17.5.e256818.7","doi-asserted-by":"crossref","unstructured":"Alpini G , Alvaro D , Marzioni M , et al . The pathophysiology of biliary epithelia. In: Ursodeoxycholic Acid Treatment of Vanishing Bile Duct Syndromes. CRC Press, 2020: 404\u201315. Available: https:\/\/www.taylorfrancis.com\/books\/9781000716849","DOI":"10.1201\/9780367813888-33"},{"key":"2025082708312648000_17.5.e256818.8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/MPH.0b013e31818b37c4","article-title":"Vanishing bile duct syndrome and Hodgkin disease","volume":"30","author":"Pass","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082708312648000_17.5.e256818.9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep4.1088","article-title":"Drug-induced cholestasis","volume":"1","author":"Sundaram","year":"2017","journal-title":"Hepatol Commun"},{"key":"2025082708312648000_17.5.e256818.10","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1962.03620240054009"},{"key":"2025082708312648000_17.5.e256818.11","unstructured":"O\u2019Grady JG , Lake JR , Howdle PD . Comprehensive Clinical Hepatology.2006:537547."},{"key":"2025082708312648000_17.5.e256818.12","doi-asserted-by":"publisher","DOI":"10.1007\/s005340170002"},{"key":"2025082708312648000_17.5.e256818.13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/21548331.1990.11703976","article-title":"Disappearing bile ducts: immunologic mechanisms","volume":"25","author":"Vierling","year":"1990","journal-title":"Hosp Pract"},{"key":"2025082708312648000_17.5.e256818.14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00007890-199301000-00016","article-title":"Detection of circulating intercellular adhesion molecule-1 after liver transplantation-evidence of local release within the liver during graft rejection","volume":"55","author":"Adams","year":"1993","journal-title":"Transplantation"},{"key":"2025082708312648000_17.5.e256818.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(88)80482-3"},{"key":"2025082708312648000_17.5.e256818.16","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"2025082708312648000_17.5.e256818.17","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1186"},{"key":"2025082708312648000_17.5.e256818.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"2025082708312648000_17.5.e256818.19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197912)44:6<2324::AID-CNCR2820440648>3.0.CO;2-8"},{"key":"2025082708312648000_17.5.e256818.20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861001)58:7<1437::AID-CNCR2820580710>3.0.CO;2-A"},{"key":"2025082708312648000_17.5.e256818.21","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701644078"},{"key":"2025082708312648000_17.5.e256818.22","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000000548","article-title":"Vanishing bile duct syndrome in Hodgkin\u2019s lymphoma: a single center experience and clinical pearls","volume":"50","author":"Bakhit","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"2025082708312648000_17.5.e256818.23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3960\/jslrt.21035","article-title":"Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events","volume":"62","author":"Ishitsuka","year":"2022","journal-title":"J Clin Exp Hematop"},{"key":"2025082708312648000_17.5.e256818.24","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.clml.2015.11.015","article-title":"Single-agent brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment","volume":"16","author":"Gupta","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082708312648000_17.5.e256818.25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227676","article-title":"Brentuximab Vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin\u2019s lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure","volume":"12","author":"Fong","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025082708312648000_17.5.e256818.26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab Vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082708312648000_17.5.e256818.27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2018.07.004","article-title":"Adverse reactions related to brentuximab vedotin use: a real-life retrospective study","volume":"74","author":"Clarivet","year":"2019","journal-title":"Therapies"},{"key":"2025082708312648000_17.5.e256818.28","unstructured":"Adcetris\/Brentuximab Vedotin [package insert]. Seattle Genetics, Inc; 2011."},{"key":"2025082708312648000_17.5.e256818.29","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7"},{"key":"2025082708312648000_17.5.e256818.30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh465"},{"key":"2025082708312648000_17.5.e256818.31","first-page":"1032","article-title":"Treatment of early-stage Hodgkin\u2019s disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity","volume":"85","author":"Brusamolino","year":"2000","journal-title":"Haematologica"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:31:36Z","timestamp":1756308696000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bcr-2023-256818"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256818","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}